Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Sandoz Receives FDA Approval for ENZEEVU™
Sandoz has secured FDA approval for ENZEEVU™ (aflibercept-abzv), a biosimilar to EYLEA®, to treat retinal conditions like wet age-related macular degeneration (AMD) and diabetic retinopathy. This approval strengthens Sandoz’s U.S. biosimilar portfolio, offering a cost-effective alternative for managing retinal diseases.…
LENSAR Receives EU Certification for ALLY®
First EU ALLY Commercial Installation Expected in August 2024 ORLANDO, Fla.—LENSAR, Inc. (Nasdaq: LNSR), a global medical technology company specializing in advanced laser solutions for cataract treatment, announced that the ALLY Adaptive Cataract Treatment System has achieved certification under the…
Top 5 Misconceptions About LASIK Surgery
LASIK surgery has revolutionized the field of vision correction, providing millions of people with clearer vision and freedom from glasses or contact lenses. However, myths and misconceptions surrounding LASIK surgery persist, causing uncertainty and misinformation. Let’s debunk the top 5…
Exclusive: Key Events at ESCRS 2024
The 42nd of the European Society of Cataract and Refractive Surgeons (ESCRS) is poised to offer a dynamic array of events and initiatives in 2024, featuring a mix of educational programs, commemorative milestones, and new insights into key areas of…
FDA Notifies Ocugen to Begin Expanded Access Program RP
The FDA has authorized Ocugen, Inc. to launch an expanded access program (EAP) for patients aged 18 and older with retinitis pigmentosa (RP), providing early access to its promising gene therapy candidate, OCU400. The treatment has shown encouraging results in…
Bausch + Lomb’s TENEO Laser Achieves Strong LASIK Outcomes
Bausch + Lomb recently published the results of a pivotal clinical trial for its TENEO™ Excimer Laser in the Journal of Refractive Surgery. This study, which played a crucial role in securing U.S. FDA approval for the device in January…
Ocular Therapeutix Enrolls First Patient in Phase 3 Wet AMD Study
Ocular Therapeutix announced that the first patients have been enrolled in its Phase 3 SOL-R clinical trial. This study aims to assess the repeat dosing of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for treating wet age-related macular degeneration…
Eyenovia and SGN Nanopharma to Develop Dry Eye Treatment
Eyenovia and SGN Nanopharma have announced a new collaboration to develop a treatment for chronic dry eye disease. Eyenovia, known for its two FDA-approved products and a late-stage asset in pediatric progressive myopia, will work with SGN Nanopharma to develop…
Elon Musk’s Blindsight Implant Faces Skepticism from Researchers
Elon Musk recently announced on X that Blindsight, a cortical implant to restore vision, would have low resolution at first “but may ultimately exceed normal human vision.” Skepticism from University of Washington Research New research from the University of Washington…
Researchers Discover Potential Therapeutic Target for Dry AMD
Researchers from the National Institutes of Health (NIH) have made a significant breakthrough in understanding the dysfunction associated with waste removal in the retina, offering new insights into dry age-related macular degeneration (AMD). A recent report from NIH and Johns…